According to incomplete statistics from the People's Daily health client, 8 pharmaceutical companies have sold assets, equity or transferred technology in the past month, and have successively started to sell. In the face of the fiercely competitive pharmaceutical market, enterprises can effectively focus on business and enhance competitiveness through public listing transfer, sale, etc., and for small and medium-sized pharmaceutical companies that do not have market competitive products, opening a "slimming" model may also be another way out of development.
Yunnan Baiyao: 100% of the equity of its third-level wholly-owned subsidiary was transferred to the group company
Yunnan Baiyao Group. According to the official website of Yunnan Baiyao
On December 31, 2021, Yunnan Baiyao Group Co., Ltd. announced that Yunnan Baiyao Group Health Products Co., Ltd., a wholly-owned subsidiary of the second-level subsidiary, intends to transfer 100% of the equity of Shanghai Yunzhen Medical Technology Co., Ltd., a third-level wholly-owned subsidiary of the company, directly held by the company, to the group company at a net book value of 625,800 yuan, free of charge.
According to the enterprise investigation, Shanghai Yunzhen Medical Technology Co., Ltd. was established in January 2021, the industry is the technology promotion and application service industry, the business scope includes: technical services, technology development, technical consulting, technical exchanges, technology transfer, technology promotion; hospital management; health consulting services (excluding diagnosis and treatment services); brand management; conference and exhibition services; etiquette services; enterprise management consulting (in addition to projects that must be approved according to law, with business licenses to carry out business activities in accordance with the law).
Lisheng Pharmaceutical: It is proposed to transfer the assets of the biochemical pharmaceutical vaccine factory
On December 31, 2021, Tianjin Lisheng Pharmaceutical Co., Ltd. issued an announcement that in order to improve operational efficiency, reduce operating costs, and optimize the company's asset structure, it terminated the 23-valent pneumococcal polysaccharide vaccine project of Tianjin Biochemical Pharmaceutical Co., Ltd., and planned to transfer the assets of the biochemical pharmaceutical vaccine factory.
The vaccine factory covers an area of 20,999.9 square meters and is valid from December 15, 2010 to December 14, 2060. As of November 30, 2021, the original value of the fixed assets of the vaccine factory area to be transferred was 254.2066 million yuan, with a net value of 152.5557 million yuan, and the original value of land assets was 6.2981 million yuan and the net value was 4.944 million yuan.
Xianju Pharmaceutical: Publicly listed transfer of 61.2% of the equity of the subsidiary
On January 17, Zhejiang Xianju Pharmaceutical Co., Ltd. issued an announcement on the proposed public listing and transfer of 61.2% of the equity of Haisheng Pharmaceutical, a holding subsidiary: "Taizhou Haisheng Pharmaceutical Co., Ltd. is a holding subsidiary of Zhejiang Xianju Pharmaceutical Co., Ltd., with a registered capital of 5 million yuan, and the company holds 61.2% of the equity of Haisheng Pharmaceutical. Subsidiary Haisheng Pharmaceutical's main business is vitamin D3 API manufacturing, follow-up production transformation, new product expansion, etc. need continuous investment, with uncertainty, Xianju Pharmaceutical will focus on the main business of steroid hormones according to the development plan, so choose the public listing method, at no less than the equity value corresponding to the target appraisal value, public listing transfer of 61.2% of the equity held by the company in Haisheng Pharmaceutical. ”
In 2021, in addition to the public transfer of equity, Xianju Pharmaceutical also transferred some of the waste machinery and equipment assets in the chengnan factory area at a transaction price of 20.3316 million yuan; in order to optimize the industrial structure and focus on the main business, Xianju Pharmaceutical has made a lot of efforts. According to the performance report released by it for the first three quarters of 2021, the company's main revenue was 3.317 billion yuan, up 13.07% year-on-year; the net profit attributable to the mother was 459 million yuan, up 28.11% year-on-year.
Tai'an Tang Pharmaceutical: Transfer of 100% equity of Tai'an Investment and Development Co., Ltd
On December 14, 2021, Guangdong Tai'an Tang Pharmaceutical Co., Ltd. announced that it would transfer its wholly-owned equity interest in Shantou Taian Investment and Development Co., Ltd. to Shantou Real Estate Hexin Co., Ltd. for a total consideration of RMB240 million.
According to the website of Guangdong Tai'antang Pharmaceutical Co., Ltd., Tai'antang Group is a national high-tech listed company that concentrates pharmaceutical research and development, production and sales, with 5 national protected varieties of traditional Chinese medicine, 28 exclusive drug production varieties, 83 "National Essential Drugs Catalog" varieties, 175 medical insurance catalogue varieties and other nearly 400 drug approvals, of which "Tai'antang Qilin Pill Production Technology" was selected into the list of national intangible cultural heritage representative projects.
Xiangxue Pharmaceutical: Transfer of 100% equity of subsidiary
On December 15, Guangzhou Xiangxue Pharmaceutical Co., Ltd. issued an evening announcement that Guangzhou Xiangxue Health Industry Equity Investment Management Co., Ltd., a wholly-owned subsidiary, signed an Equity Transfer Agreement with Guangzhou Huayao Business Management Co., Ltd. to transfer 100% of the equity of its subsidiary, Guangdong Jiuji Daily Health Products Co., Ltd., to Huayao Commerce for 33 million yuan through equity transfer.
Boji Pharmaceutical: All technical achievements and intellectual property rights of the "saltpeter glyceride granules" project were transferred to Kangyuan Pharmaceutical
On December 21, 2021, Boji Pharmaceutical Technology Co., Ltd. issued an announcement that it agreed to transfer all the technical achievements and intellectual property rights of the "Saltpeter Ganju Pellet" project to Kangyuan Pharmaceutical, and the total technology transfer fee of the project was RMB 12 million.
Shuangcheng Pharmaceutical: Grants Baishan Pharmaceutical specific intellectual property rights and production technology
On January 7, 2022, Hainan Shuangcheng Pharmaceutical Co., Ltd. announced that it agreed that Ningbo Shuangcheng Pharmaceutical Co., Ltd., a holding subsidiary of the Company, intends to grant to Baishan Pharmaceutical (Huzhou) Co., Ltd. the right to own specific intellectual property rights and production technologies related to memantine hydrochloride tablets (5mg, 10mg) in the designated area for RMB6 million.
Asia Pacific Pharmaceutical: Shares transferred to Ningbo Fubon Holding Group Co., Ltd
On January 12, Zhejiang Asia-Pacific Pharmaceutical announced that the Shaoxing Branch of the Company's shareholder, Bank of Ningbo Co., Ltd., intends to transfer 39,000,000 shares of Asia-Pacific Pharmaceutical (accounting for 7.27% of the company's total share capital) held by the Company to Ningbo Fubon Holding Group Co., Ltd., the Company's largest shareholder, through an agreement transfer. The total transfer price is RMB203.19 million.
(Chen Linhui sorted out according to public information such as pharmaceutical company announcements, financial reports and official websites of enterprises)
![In Shenzhen, Guangdong Province, Ms. Wu used color-changing glass to make the Beijing Winter Olympics mascot "glass pier" pendant, which is exquisite, exquisite and transparent, very cute, hanging on the chest, "glass."[fig]](data:image/gif;base64,R0lGODlhAQABAIAAAP///wAAACwAAAAAAQABAAACAkQBADs=)